Abstract
Rationale
The abuse of over-the-counter (OTC) medications has been widely reported. However, there are few preclinical studies examining the behavioral effects of OTC medications at higher, abused doses.
Objectives
The objectives of the current study were to determine whether the anti-histamine diphenhydramine (DIP) and the antitussive dextromethorphan (DEX), either alone or in combination, would have stimulant properties and be self-administered in animals.
Methods
For drug self-administration, naive rats with no history of exposure to other drugs were trained to self-administer IV DEX+DIP (0.5+0.5, 1+1 or 2+2 mg/kg per injection), DEX alone (1 mg/kg) or DIP (1 mg/kg) alone under five-response fixed-ratio (FR) schedule with a 30-s time-out after each injection in 2-h sessions 3–5 days a week. Separate groups of rats were tested on locomotor activity. After 8 consecutive days of habituation, naive rats were injected with 3, 10, or 30 mg/kg DEX or DIP alone IP, or in combination of 3+3 mg/kg, 10+10 mg/kg, or 30+30 mg/kg DEX+DIP IP. Saline was injected IP during the intervening days. Locomotor activity was measured for each session.
Results
DEX+DIP combinations were self-administered, but the drugs alone were not. The acquisition of DEX+DIP self-administration was rapid with a majority of rats reaching the final FR5 schedule in 22–23 sessions. The total IV combination dose for each final scheduled session ranged from 40 mg/kg to 160 mg/kg DEX+DIP. Significant increases in locomotor activity were observed for DIP, an effect that was significantly enhanced when DIP was given in combination with DEX. Significant mortality was also observed for the drug combination at each dose tested when given IV, with the highest mortality following the highest dose (2+2 mg/kg). When given IP, no mortality was observed.
Conclusions
These results show that combinations of DEX and DIP have stimulant properties and are self-administered by animals. Abuse of this combination in humans would be expected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abekawa T, Ohmori T, Ito K, Koyama T (2000) D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res 867:250–254
Adriani W, Felici A, Sargolini F, Roullet P, Usiello A, Oliverio A, Mele A (1998) N-Methyl-d-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp Brain Res 123:52–59
Beardsley PM, Balster RL (1992) The intravenous self-administration of antihistamines by rhesus monkeys. Drug Alcohol Depend 30:117–126
Bergman J, Spealman RD (1986) Some behavioral effects of histamine H1 antagonists in squirrel monkeys. J Pharmacol Exp Ther 239:104–110
Cranston JW, Yoast R (1999) Abuse of dextromethorphan. Arch Family Med 8:99–100
Dringenberg HC, de Souza-Silva MA, Schwarting RKW, Huston JP (1998) Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Naunyn-Schmiedeberg’s Arch Pharmacol 358:423–429
Elliott K, Hynansky A, Inturrisi CE (1994) Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 59:361–368
Galeotti N, Ghelardini C, Bartolini A (1999) The role of potassium channels in antihistamine analgesia. Neuropharmacology 38:1893–1901
Gardner DM, Kutcher S (1993) Dimenhydrinate abuse among adolescents. Can J Psychiatry 38:114–116
Gauvin DV, Vanecek SA, Baird TJ, Valett M, Briscoe RJ, Carl KL, Holloway FA, Sannerud CA (1998) The stimulus properties of two common over-the-counter drug mixtures: dextromethorphan+ephedrine and dextromethorphan+diphenhydramine. J Psychopharmacol 12:84–92
Halpert AG, Olmstead MC, Beninger RJ (2002) Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev 26:61–67
Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J (1998) In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 26:536–539
Hart CL, Haney M, Foltin RW, Fischman MW (2002) Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology 164:376–384
Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar JK (2000) Dextromethorphan and its metabolite dextrorphan block α3β4 neuronal nicotinic receptors. J Pharmacol Exp Ther 293:962–967
Jasinski DR (2000) Abuse potential of morphine/dextromethorphan combination. J Pain Symptom Manage 19:S26–S30
Jun JH, Schindler CW (2000) Dextromethorphan alters methamphetamine self-administration in the rat. Pharmacol Biochem Behav 67:405–409
Kuo CC, Huang RC, Lou BS (2000) Inhibition of Na+ current by diphenhydramine and other diphenyl compounds: molecular determination of selective binding to the inactivated channels. Mol Pharmacol 57:135–145
Masukawa Y, Suzuki T, Misawa M (1993) Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines. Psychopharmacology 111:139–143
Mathe JM, Nomikos GG, Hildebrand BE, Hertel P, Svensson TH (1996) Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309:1–11
Matsunaga K, Sato T, Shuto H, Tsuruta Y, Suemaru K, Gomita Y, Oishi R (1998) Inhibition of neuronal dopamine uptake by some antiallergic drugs. Eur J Pharmacol 350:165–169
Monaghan DT, Larsen H (1997) NR1 and NR2 subunit contributions to N-methyl-d-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther 280:614–620
Murray S, Brewerton T (1993) Abuse of over-the-counter dextromethorphan by teenagers. S Med J 86:1151–1153
National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington D.C.
Newman AH, Shah JH, Izenwasser S, HJeller B, Mattson M, Tortella FC (1996) Highly selective s1 ligands based on dextromethorphan. Med Chem Res 6:102–117
Nicholson KL, Hayes B, Balster RL (1999) Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology 146:49–59
Noonan WC, Miller WR, Feeney DM (2000) Dextromethorphan abuse among young youth. Arch Fam Med 9:791–792
Plesan A, Hoffmann O, Xu XJ, Wiesenfeld-Hallin Z (1999) Genetic differences in the antinociceptive effect of morphine and its potentiation by dextromethorphan in rats. Neurosci Lett 263:53–56
Popik P, Kozela E, Danysz W (2000) Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn-Schmiedeberg’s Arch Pharmacol 361:425–432
Privou C, Knoche A, Hasenohrl RU, Huston JP (1998) The H1- and H2-histamine blockers chlorpheniramine and ranitidine applied to the nucleus basalis magnocellularis region modulate anxiety and reinforcement related processes. Neuropharmacology 37:1019–1032
Rowe C, Verjee Z, Koren G (1997) Adolescent dimenhydrinate abuse: resurgence of an old problem. J Adolesc Health 21:47–49
Sharma AN, Hexdall AH, Chang EK, Nelson LS, Hoffman RS (2003) Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. Am J Emerg Med 21:212–215
Shoaib M, Shippenberg TS, Goldberg SR, Schindler CW (1995) Behavioral studies with the glycine partial agonist (+)-HA966 on cocaine induced locomotor activity and reinforcement. Behav Pharmacol 6:568–576
Stefanski R, Ladenheim B, Lee SH, Cadet JL, Goldberg SR (1999) Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur J Pharmacol 371:123–135
Steinmiller CL, Maisonneuve IM, Glick SD (2002) Effects of dextromethorphan on dopamine release in the nucleus accumbens: interactions with morphine. Pharmacol Biochem Behav 74:803–810
Stern KN, Chait LD, Johanson C-E (1989) Reinforcing and subjective effect of oral tripelennamine in normal human volunteers. Behav Pharmacol 1:161–167
Sun CLJ, Hui FW, Hanig JP (1985) Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology 24:1–4
Suzuki T, Mori T, Takamori K, Onodera K, Misawa M (1996) Effects of H(1)-antagonists on discriminative stimulus effects of cocaine and methamphetamine in rats. Behav Pharmacol 7:111–118
Suzuki T, Mori T, Tsuji M, Misawa M, Onodera K (1997) Generalization of d-, l- and dl-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine. Behav Pharmacol 8:718–724
Unterwald EM, Kucharski LT, Williams JE, Kornetsky C (1984) Tripelennamine: enhancement of brain-stimulation reward. Life Sci 34:149–153
Ushijima I, Kobayashi T, Suetsugi M, Watanabe K, Yamada M, Yamaguchi K (1998) Cocaine: evidence for NMDA-, beta-carboline- and dopaminergic-mediated seizures in mice. Brain Res 797:347–350
Wauquier A, Niemegeers CJ (1981) Effects of chlorpheniramine, pyrilamine and astemizole on intracranial self-stimulation in rats. Eur J Pharmacol 72:245–248
Wilkinson L (1992) SYSTAT: Statistics, Version 5.2. SYSTAT, Inc., Evanston, Ill.
Wise RA (1998) Drug-activation of brain reward pathways. Drug Alcohol Depend 51:13–22
Wolfe TR, Caravati EM (1995) Massive dextromethorphan ingestion and abuse. Am J Emerg Med 13:174–176
Zawertailo LA, Kaplan HL, Busto U, Tyndale RF, Sellers E (1998) Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 18:332–337
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jun, J.H., Thorndike, E.B. & Schindler, C.W. Abuse liability and stimulant properties of dextromethorphan and diphenhydramine combinations in rats. Psychopharmacology 172, 277–282 (2004). https://doi.org/10.1007/s00213-003-1650-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1650-4